OncoMatch/Clinical Trials/NCT06442475
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Is NCT06442475 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Mosunetuzumab for ann arbor stage ii follicular lymphoma.
Treatment: Mosunetuzumab — This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: monoclonal antibody
Exception: peptide-based therapeutic vaccines are allowed
No prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are allowed.) Prior use of any monoclonal antibody within 4 weeks before the first mosunetuzumab administration
Lab requirements
Blood counts
No significant cytopenias defined as platelets < 100,000/uL, hemoglobin < 10 g/dL, or ANC < 1500/uL
Kidney function
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if Gilbert's syndrome); AST ≤ 3 x ULN; ALT ≤ 3 x ULN; GGT ≤ 3 x ULN
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation; Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if Gilbert's syndrome); AST ≤ 3 x ULN; ALT ≤ 3 x ULN; GGT ≤ 3 x ULN; No significant cytopenias defined as platelets < 100,000/uL, hemoglobin < 10 g/dL, or ANC < 1500/uL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06442475 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages